Tenax Therapeutics 将来の成長

Future 基準チェック /06

Tenax Therapeuticsは、37.9%と78.9%でそれぞれ年率37.9%で利益と収益が成長すると予測される一方、EPSはgrowで15.7%年率。

主要情報

37.9%

収益成長率

15.7%

EPS成長率

Biotechs 収益成長	28.3%
収益成長率	78.9%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	14 Nov 2024

今後の成長に関する最新情報

Recent updates

Tenax to evaluate strategic alternatives including a sale or a merger, shares rise ~7%

Sep 15

Are Insiders Selling Tenax Therapeutics, Inc. (NASDAQ:TENX) Stock?

Jan 20

業績と収益の成長予測

NasdaqCM:TENX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	N/A	-35	N/A	N/A	5
12/31/2025	N/A	-25	N/A	N/A	5
12/31/2024	N/A	-17	N/A	N/A	5
9/30/2024	N/A	-15	-12	-12	N/A
6/30/2024	N/A	-13	-11	-11	N/A
3/31/2024	N/A	-10	-9	-9	N/A
12/31/2023	N/A	-8	-6	-6	N/A
9/30/2023	N/A	-7	-6	-6	N/A
6/30/2023	N/A	-8	-8	-8	N/A
3/31/2023	N/A	-10	-10	-10	N/A
12/31/2022	N/A	-11	-11	-11	N/A
9/30/2022	N/A	-12	-12	-12	N/A
6/30/2022	N/A	-13	-12	-12	N/A
3/31/2022	N/A	-11	-11	-11	N/A
12/31/2021	N/A	-32	-11	-11	N/A
9/30/2021	N/A	-32	-10	-10	N/A
6/30/2021	N/A	-31	-9	-9	N/A
3/31/2021	N/A	-31	-10	-10	N/A
12/31/2020	N/A	-10	-9	-9	N/A
9/30/2020	N/A	-10	-9	-9	N/A
6/30/2020	N/A	-10	-8	-8	N/A
3/31/2020	N/A	-9	-8	-8	N/A
12/31/2019	N/A	-8	-8	-8	N/A
9/30/2019	N/A	-15	-7	-7	N/A
6/30/2019	N/A	-14	-7	-7	N/A
3/31/2019	N/A	-15	-6	-6	N/A
12/31/2018	N/A	-14	-6	-5	N/A
9/30/2018	N/A	-6	-6	-6	N/A
6/30/2018	N/A	-6	N/A	-5	N/A
3/31/2018	N/A	-7	N/A	-10	N/A
12/31/2017	N/A	-9	N/A	-12	N/A
9/30/2017	N/A	-37	N/A	-14	N/A
6/30/2017	N/A	-40	N/A	-17	N/A
3/31/2017	N/A	-42	N/A	-17	N/A
12/31/2016	N/A	-44	N/A	-16	N/A
9/30/2016	0	-19	N/A	-18	N/A
6/30/2016	0	-17	N/A	-17	N/A
3/31/2016	N/A	-18	N/A	-14	N/A
12/31/2015	N/A	-15	N/A	-13	N/A
10/31/2015	0	-14	N/A	-11	N/A
7/31/2015	0	-15	N/A	-12	N/A
4/30/2015	0	-14	N/A	-10	N/A
1/31/2015	0	-20	N/A	-11	N/A
10/31/2014	0	-21	N/A	-11	N/A
7/31/2014	0	-23	N/A	-10	N/A
4/30/2014	0	-25	N/A	-9	N/A
1/31/2014	1	-18	N/A	-8	N/A

アナリストによる今後の成長予測

収入対貯蓄率: TENX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: TENX今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: TENX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: TENX来年は収益がないと予測されています。

高い収益成長: TENX来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: TENXの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Tenax Therapeutics 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Forecast to breakeven in 2026

Price target increased by 16% to US$110

Forecast to breakeven in 2023

Price target decreased to US$4.00

Forecast to breakeven in 2022

Price target increased to US$4.75

Recent updates

New minor risk - Profitability

Tenax Therapeutics, Inc. announced that it has received $99.681169 million in funding from a group of investors

Tenax Therapeutics, Inc. announced that it expects to receive $99.681169 million in funding from a group of investors

New minor risk - Share price stability

Tenax Therapeutics, Inc. announced that it expects to receive $99.999996 million in funding from a group of investors

New major risk - Revenue and earnings growth

Tenax Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

New minor risk - Profitability

Tenax Therapeutics Enrolls First Patient in Phase 3 Level Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in PH-HFpEF Patients

Tenax Therapeutics, Inc. Appoints Lawrence R. Hoffman as Principal Financial Officer and Principal Accounting Officer

Tenax Therapeutics Receives Non-Compliance Notice from Nasdaq

Forecast to breakeven in 2026

Tenax Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $36 million.

Tenax Therapeutics, Inc. Appoints Javed Butler to its PH-HFpEF Scientific Advisory Board

Tenax Therapeutics, Inc. Announces FDA Clearance of IND for TNX-103 for the Treatment of Pulmonary Hypertension with Heart Failure

New major risk - Share price stability

The Nasdaq Stock Market LLC Grants Tenax Therapeutics's Request for an Extension Through March 25, 2024 to Evidence Compliance with the $1.00 Per Share Requirement for Continued Inclusion on the Nasdaq Capital Market

Tenax Therapeutics Issues U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Tenax Therapeutics, Inc. Receives a Notice of Allowance from the United States Patent and Trademark Office for its Patent Application

Price target increased by 16% to US$110

Tenax Receives Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

High number of new and inexperienced directors

Tenax Therapeutics, Inc. Announces the Presentation of Positive Data from a Study of PH-HFpEF Patients Being Treated with Oral Levosimendan

Tenax to evaluate strategic alternatives including a sale or a merger, shares rise ~7%

Tenax Therapeutics, Inc. Receives Formal Notice That the Nasdaq Stock Market LLC

Forecast to breakeven in 2023

Tenax Therapeutics, Inc. Announces Resignation of Executives

Price target decreased to US$4.00

Tenax Therapeutics, Inc. Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension

Tenax Therapeutics, Inc. announced that it expects to receive $8 million in funding from Armistice Capital LLC

High number of new and inexperienced directors

Tenax Therapeutics, Inc. Appoints Robyn Hunter to the Board of Directors

Tenax Therapeutics Provides Update on TNX-102, TNX-103 and TNX-201 Clinical Programs

High number of new and inexperienced directors

Forecast to breakeven in 2022

Price target increased to US$4.75

Independent Director James Mitchum has left the company

Tenax Therapeutics, Inc. Announces New Publication Highlighting Novel Levosimendan Mechanism of Action in Pulmonary Hypertension Patients with Heart Failure and Preserved Ejection Fraction

High number of new directors

CEO & Director Anthony DiTonno has left the company

Independent Director Chris Rallis has left the company

Independent Director Gregory Pepin has left the company

Independent Chairman Ronald Blanck has left the company

Price target increased to US$4.75

Tenax Therapeutics, Inc. Expands Board of Directors

New 90-day high: US$2.78

Tenax Therapeutics, Inc. (NasdaqCM:TENX) acquired PH Precision Med Inc. for $21.6 million.

Are Insiders Selling Tenax Therapeutics, Inc. (NASDAQ:TENX) Stock?

New 90-day high: US$2.36

New 90-day high: US$1.98

Tenax Therapeutics, Inc. Announces Presentation of 24-Hour HELP Study Results at the American Heart Association Scientific Sessions 2020

New 90-day low: US$1.18

Tenax Therapeutics, Inc. Enters into Amendment to License Agreement with Orion Corporation

Tenax Therapeutics Announces Late-Breaking Clinical Trial Presentation of Phase 2 HELP Study at Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting

New 90-day high: US$1.63

Price target lowered to US$4.23

Tenax Therapeutics, Inc. announced that it has received $4.735325 million in funding

Tenax Therapeutics, Inc. announced that it expects to receive $4.735325 million in funding

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘